Front Aging Neurosci:模拟运动或可改善阿尔兹海默氏症患者的病情

2016-04-07 佚名 生物谷

据美国阿尔兹海默氏症协会数据显示,阿尔兹海默氏症是引发美国人死亡的第六大原因,目前并没有有效的疗法和途径来减缓或抑制患者的病情进展,但患者可以通过机体和认知康复来获益,而且研究者目前也正在研究是否模仿行为可以作为一种有效工具来帮助重拾患者失去的能力。 近日,一项刊登于国际杂志Frontiers in Aging Neuroscience上的研究论文中,来自热那亚大学(University of

据美国阿尔兹海默氏症协会数据显示,阿尔兹海默氏症是引发美国人死亡的第六大原因,目前并没有有效的疗法和途径来减缓或抑制患者的病情进展,但患者可以通过机体和认知康复来获益,而且研究者目前也正在研究是否模仿行为可以作为一种有效工具来帮助重拾患者失去的能力。

近日,一项刊登于国际杂志Frontiers in Aging Neuroscience上的研究论文中,来自热那亚大学(University of Genoa)的研究人员通过研究发现,进行动作模仿或可帮助减缓阿尔兹海默氏症患者的症状;研究者指出,患者可以模拟人类简单的姿势或者电脑屏幕上移动的点,而这样的运动方式或许可以补充当前阿尔兹海默氏症的治疗策略。

重复别人的行为是一种基本的社会构建模块,其可以帮助人们去学习并且同他人交际,研究者Bisio指出,通过复制母亲的行为活动,婴儿就可以学会如何与人联系,而相同的原则也在网球学生中可以体现出来,网球学生可以向训练者学习如何进行网球的接发,相关研究结果就表明,模仿行为或许也可以用于帮助阿尔兹海默氏症患者进行疾病恢复。

研究初期,科学家们并不确定是否具有多种连线的大脑功能在疾病刚开始造成损伤的时候就发挥作用,实际上阿尔兹海默氏症会以一种特殊的方式来毁灭大脑的某些功能,而本文研究中研究者发现,患者处于轻度疾病状态时可以保持自身的模仿能力,同时患者还可以很好地完成其训练者交给的模仿任务。

而基于电脑的训练方法可以为患者提供另外一种治疗方法,据研究者介绍,利用电脑进行训练是可能的,但以训练者为基础的训练方式或许更加有用,而这或许是因为患者在与训练者在接触交流过程中所产生的情绪反应所带来的益处要优于电脑的模拟训练。

最后研究者说道,由于阿尔兹海默氏症损坏了大脑中连接运动和认知功能的部分,而行为疗法对于患者而言非常重要,甚至在药物疗法后依然如此;通过让阿尔兹海默氏症患者模拟某些简单的行为活动获为后期开发更好的策略来改善或治疗阿尔兹海默氏症提供新的线索和希望。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1764982, encodeId=8b2b1e649824e, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1dc37824931, createdName=ms7524819409032184, createdTime=Sun Mar 19 21:06:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78343, encodeId=9687e834353, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 19:02:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78344, encodeId=3481e83445e, content=d值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 19:02:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364106, encodeId=edfa1364106b4, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Apr 09 00:06:00 CST 2016, time=2016-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402681, encodeId=7fd81402681e5, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat Apr 09 00:06:00 CST 2016, time=2016-04-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1764982, encodeId=8b2b1e649824e, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1dc37824931, createdName=ms7524819409032184, createdTime=Sun Mar 19 21:06:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78343, encodeId=9687e834353, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 19:02:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78344, encodeId=3481e83445e, content=d值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 19:02:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364106, encodeId=edfa1364106b4, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Apr 09 00:06:00 CST 2016, time=2016-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402681, encodeId=7fd81402681e5, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat Apr 09 00:06:00 CST 2016, time=2016-04-09, status=1, ipAttribution=)]
    2016-04-14 李继凯

    高大上的文章

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1764982, encodeId=8b2b1e649824e, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1dc37824931, createdName=ms7524819409032184, createdTime=Sun Mar 19 21:06:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78343, encodeId=9687e834353, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 19:02:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78344, encodeId=3481e83445e, content=d值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 19:02:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364106, encodeId=edfa1364106b4, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Apr 09 00:06:00 CST 2016, time=2016-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402681, encodeId=7fd81402681e5, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat Apr 09 00:06:00 CST 2016, time=2016-04-09, status=1, ipAttribution=)]
    2016-04-14 李继凯

    d值得学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1764982, encodeId=8b2b1e649824e, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1dc37824931, createdName=ms7524819409032184, createdTime=Sun Mar 19 21:06:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78343, encodeId=9687e834353, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 19:02:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78344, encodeId=3481e83445e, content=d值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 19:02:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364106, encodeId=edfa1364106b4, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Apr 09 00:06:00 CST 2016, time=2016-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402681, encodeId=7fd81402681e5, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat Apr 09 00:06:00 CST 2016, time=2016-04-09, status=1, ipAttribution=)]
    2016-04-09 lsndxfj
  5. [GetPortalCommentsPageByObjectIdResponse(id=1764982, encodeId=8b2b1e649824e, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1dc37824931, createdName=ms7524819409032184, createdTime=Sun Mar 19 21:06:00 CST 2017, time=2017-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78343, encodeId=9687e834353, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 19:02:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78344, encodeId=3481e83445e, content=d值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 19:02:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364106, encodeId=edfa1364106b4, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Apr 09 00:06:00 CST 2016, time=2016-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402681, encodeId=7fd81402681e5, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat Apr 09 00:06:00 CST 2016, time=2016-04-09, status=1, ipAttribution=)]

相关资讯

Science:科学家首次模拟出关键视觉蛋白的特殊行为

近日,一篇刊登于国际杂志Science上的研究论文中,来自英国布里斯托尔大学的研究人员通过研究人工模拟出了一种关键的光敏分子,或可帮助开发新型方法来制造光敏人工细胞。 文章中,研究人员Jonathan Clayden及其同事开发了一种人工模拟的视网膜紫质,视网膜紫质是一种位于视网膜细胞膜中的特殊蛋白,通过视网膜紫质进行的光吸收是视觉生物化学作用的第一步。 利用结合在细胞膜上的某些抗生素的分子

Nature:神经细胞的重生之谜

长期以来神经科学家一直认为瘢痕组织是通过神经胶质细胞形成的,神经胶质细胞是中枢神经系统中围绕在神经元周围的特殊细胞,当大脑或脊髓受损时其可以阻碍损伤的神经细胞继续生长,因此难怪研究者们会假设如果他们寻找到一种移除或中和疤痕组织的方法,那么损伤的神经元细胞或许就会进行自我修复。 近日刊登在国际杂志Nature上的一项研究论文中,来自加州大学洛杉矶分校的研究人员通过研究发现,研究者们的上述假设或许

Cell:特殊脂肪组织如何开启机体的节能模式

近日,来自德国马克斯普朗克研究所(Max Planck Institute)的研究人员通过研究发现,大脑细胞不仅会告知饥饿的小鼠去寻找食物,而且还会通过机体棕色脂肪来限制血糖的使用,该机制或可确保在食物量不足的情况下小鼠依然保持足够的生存率,相关研究刊登于国际杂志Cell上。 当我们饥饿的时候会发生什么?我们的大脑如何控制能量消耗?为了回答这些问题,研究人员Jens Bruning及其同事分析

Nature:生男还是生女?古老病毒来决定

近日,一项刊登在Nature杂志上的研究中,来自耶鲁大学的科学家发表了一项突破性的研究成果,他们发现人类及其他哺乳动物的性别早在150万年前就由“嵌入”哺乳动物基因组中的关键病毒的一种简单修饰所确定了。研究者Andrew Xiao指出,从根本上来说,这些病毒可以促使哺乳动物的基因组不断进化,但同时其却带来了一定的不确定性,除了胚胎之外,科学家们发现这些病毒活跃的场所就是人类机体的肿瘤和神经元

Nature:科学家揭秘常见脑血管疾病的发病机制

大脑海绵状血管畸形(CCMs)是大脑中薄壁血管膨胀的一种集群形式,其会引发中风和癫痫发作,然而具体发病机制目前研究者尚不清楚;近日来自宾夕法尼亚大学的研究人员通过研究发现了隐藏在这种脑血管疾病发生背后的一种新型的分子机制,相关研究刊登于Nature杂志上。 通常在100至200人中会有一名大脑海绵状血管畸形患者,该疾病主要表现为两种方式,第一种是散发状态,占到了80%的患者,另外一种则是遗传性

如果人类都吃素,世界将会怎样?

就算你不是一名素食主义者,那么你身边也肯定至少有一位只吃素的朋友。根据所在的国家地区不同,周围的素食主义者群体的规模也可大可小。例如,美国境内的素食主义者占据4%-5%,然而在印度则高达30%。我们不妨假设一下, 如果全世界都是素食主义者的话,世界将会怎么样呢? 研究结果显示,如果这种情况真的出现,那么将有200亿只肉鸡,150亿只肉牛以及超过10亿只肉羊将会失去使用价值。 难以想象,如果我